Evaluation of the prognostic benefit of identifying the probable primary site in cancer of unknown primary

[1] Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2011 Sep [cited 2015 May 22];22 Suppl 6:vi64-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2190850710.1093/annonc/mdr38921908507Search in Google Scholar

[2] Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer [Internet]. 2013 Jan [cited 2015 Sep 30];13:36. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3565900&tool=pmcentrez&rendertype=abstract10.1186/1471-2407-13-36356590023356713Search in Google Scholar

[3] Brustugun OT, Helland Å. Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol [Internet]. 2014 Jan [cited 2015 Sep 29];53(1):134-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2355095710.3109/0284186X.2013.78323023550957Search in Google Scholar

[4] Mnatsakanyan E, Tung W-C, Caine B, Smith- Gagen J. Cancer of unknown primary: time trends in incidence, United States. Cancer Causes Control [Internet]. 2014 Jun [cited 2015 Sep 29];25(6):747-57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2471066310.1007/s10552-014-0378-224710663Search in Google Scholar

[5] Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer [Internet]. 2013 Sep 3 [cited 2015 Sep 29];109(5):1318-24. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3778275&tool=pmcentrez&rendertype=abstract10.1038/bjc.2013.386377827523860528Search in Google Scholar

[6] Schwartz AM, Harpaz N. A primary approach to cancers of unknown primary. J Natl Cancer Inst [Internet]. 2013 Jul 5 [cited 2015 Jul 31];105(11):759-61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2364104410.1093/jnci/djt11523641044Search in Google Scholar

[7] Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of Unknown Primary Site: Missing Primary or Missing Biology? Oncologist [Internet]. 2007 Apr 1 [cited 2015 Sep 30];12(4):418-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1747068410.1634/theoncologist.12-4-41817470684Search in Google Scholar

[8] Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol [Internet]. 2002 Dec 15 [cited 2015 Jun 1];20(24):4679-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1248841310.1200/JCO.2002.04.01912488413Search in Google Scholar

[9] Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol [Internet]. 1994;12(6):1272-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/820138910.1200/JCO.1994.12.6.12728201389Search in Google Scholar

[10] Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res [Internet]. 1999;5(11):3403-10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10589751Search in Google Scholar

[11] Trivanovic D, Petkovic M, Stimac D. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer [Internet]. 2007 Jun 15 [cited 2015 Sep 30];109(12):2623-4; author reply 2624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1748785810.1002/cncr.2270917487858Search in Google Scholar

[12] Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer [Internet]. 2006 Dec 1 [cited 2015 Sep 30];107(11):2698-705. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1706350010.1002/cncr.2230017063500Search in Google Scholar

[13] Lu H-J, Chen K-W, Tzeng C-H, Liu J-H, Chiou T-J, Yen C-C, et al. Evaluation of prognosis for carcinoma of unknown origin in elderly patients. Oncology [Internet]. 2012 Jan [cited 2015 Sep 30];83(1):24-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2272248410.1159/00033798322722484Search in Google Scholar

[14] Chen K-W, Liu C-J, Lu H-J, Tzeng C-H, Liu J-H, Chiou T-J, et al. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study. BMC Res Notes [Internet]. 2012 Jan [cited 2015 Sep 30];5:70. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3331815&tool=pmcentrez&rendertype=abstract10.1186/1756-0500-5-70333181522280526Search in Google Scholar

[15] Penel N, Negrier S, Ray-Coquard I, Ferte C, Devos P, Hollebecque A, et al. Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One [Internet]. 2009 Jan [cited 2015 Sep 30];4(8):e6483. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2715134&tool=pmcentrez&rendertype=abstract10.1371/journal.pone.0006483271513419649260Search in Google Scholar

[16] Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol [Internet]. 2010 Jun [cited 2015 Sep 30];21(6):1163-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2001908810.1093/annonc/mdp58320019088Search in Google Scholar

[17] Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J. Prognostic factors in cancer of unknown primary site. Tumori [Internet]. Jan [cited 2015 Sep 30];96(1):111-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2043786710.1177/030089161009600118Search in Google Scholar

[18] Van de Wouw AJ, Jansen RLH, Griffioen AW, Hillen HFP. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res [Internet]. Jan [cited 2015 Sep 30];24(1):297-301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15015611Search in Google Scholar

[19] Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev [Internet]. 2013 Nov [cited 2015 Sep 30];39(7):701-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2356657310.1016/j.ctrv.2013.03.00123566573Search in Google Scholar

[20] Trivanović D, Petkovic M, Stimac D. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Clin Oncol (R Coll Radiol) [Internet]. 2009 Mar [cited 2015 Sep 30];21(1):43-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1897689410.1016/j.clon.2008.09.00718976894Search in Google Scholar

[21] Randén M, Helde-Frankling M, Runesdotter S, Gunvén P. Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience. Med Oncol [Internet]. 2013 Dec [cited 2015 Sep 30];30(4):706. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2404593110.1007/s12032-013-0706-524045931Search in Google Scholar

[22] Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O’Kelly P, et al. Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol [Internet]. 2002 Dec [cited 2015 Sep 30];57(12):1073-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1247553110.1053/crad.2002.108512475531Search in Google Scholar

[23] Pavlidis N. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol [Internet]. 2012 Sep [cited 2015 Sep 30];23 Suppl 1:x282-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2298797810.1093/annonc/mds317Search in Google Scholar

[24] Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site. Oncology (Williston Park) [Internet]. 2000 Apr [cited 2015 Sep 30];14(4):563-74; discussion 574-6, 578-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10826316Search in Google Scholar

[25] Varadhachary G. Carcinoma of Unknown Primary Site: The Poster Child for Personalized Medicine? JAMA Oncol [Internet]. 2015 Apr 1 [cited 2015 Aug 18];1(1):19-21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2618229910.1001/jamaoncol.2014.277Search in Google Scholar

[26] Hainsworth JD, Rubin MS, Spigel DR, Boccia R V, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol [Internet]. 2013 Jan 10 [cited 2015 Sep 30];31(2):217-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2303262510.1200/JCO.2012.43.3755Search in Google Scholar

[27] Greco FA. Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis. Am Soc Clin Oncol Educ Book [Internet]. 2013 Jan [cited 2015 Sep 30];175-81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2371449310.14694/EdBook_AM.2013.33.175Search in Google Scholar

[28] Stella GM, Senetta R, Cassenti A, Ronco M, Cassoni P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med [Internet]. 2012 Jan [cited 2015 Jun 1];10:12. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3315427&tool=pmcentrez&rendertype=abstract10.1186/1479-5876-10-12Search in Google Scholar

[29] Schapira D V, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med [Internet]. 1995 Oct 23 [cited 2015 Jun 1];155(19):2050-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/757506310.1001/archinte.155.19.2050Search in Google Scholar

[30] Hamilton CS, Langlands AO. ACUPS (adenocarcinoma of unknown primary site): a clinical and cost benefit analysis. Int J Radiat 1 Hamilt CS, Langlands AO ACUPS (adenocarcinoma Unkn Prim site) a Clin cost benefit Anal Int J Radiat Oncol Biol Phys [Internet] 1987 Oct [cited 2015 Jun 1];13(10)1497-503 Available from ht [Internet]. 1987 Oct [cited 2015 Jun 1];13(10):1497-503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/311418110.1016/0360-3016(87)90317-8Search in Google Scholar

[31] Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol [Internet]. 2012 Feb [cited 2015 May 22];23(2):298-304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2170913810.1093/annonc/mdr30621709138Search in Google Scholar

[32] Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol [Internet]. 2009 Jun [cited 2015 Jun 1];11(6):340-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1953144810.1007/s12094-009-0367-119531448Search in Google Scholar

[33] Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer [Internet]. 2004 May 1 [cited 2015 Jun 1];100(9):1776-85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1511225610.1002/cncr.2020215112256Search in Google Scholar

[34] Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol [Internet]. 2013 Jul [cited 2015 Sep 30];37(7):1067-75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2364846410.1097/PAS.0b013e31828309c4526658923648464Search in Google Scholar

[35] Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol [Internet]. 2012 Sep [cited 2015 Sep 14];23 Suppl 1:x271-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2298797510.1093/annonc/mds35722987975Search in Google Scholar

[36] Varadhachary G. New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling. Clin Cancer Res [Internet]. 2013 Mar 21 [cited 2015 Sep 30];19(15):4027-33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2351989810.1158/1078-0432.CCR-12-303023519898Search in Google Scholar

[37] Boyland L, Davis C. Patients’ experiences of carcinoma of unknown primary site: dealing with uncertainty. Palliat Med [Internet]. 2008 Mar [cited 2015 Sep 30];22(2):177-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1837238210.1177/026921630708534118372382Search in Google Scholar

[38] Hyphantis T, Papadimitriou I, Petrakis D, Fountzilas G, Repana D, Assimakopoulos K, et al. Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology [Internet]. 2013 Sep [cited 2015 Sep 30];22(9):2009-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23359412 10.1002/pon.324423359412Search in Google Scholar